Anticancer actions of PPARγ ligands: Current state and future perspectives in human lung cancer
Author:
Open Access
- 1 January 2010
- journal article
- Published by Baishideng Publishing Group Inc. in World Journal of Biological Chemistry
- Vol. 1 (3) , 31-40
Abstract
Peroxisome proliferator-activated receptors (PPARs) are ligand-dependent nuclear transcription factors and members of the nuclear receptor superfamily. Of the three PPARs identified to date (PPARγ, PPARβ/δ, and PPARα), PPARγ has been studied the most, in part because of the availability of PPARγ agonists (also known as PPARγ ligands) and its significant effects on the management of several human diseases including type 2 diabetes, metabolic syndrome, cardiovascular disease and cancers. PPARγ is expressed in many tumors including lung cancer, and its function has been linked to the process of lung cancer development, progression and metastasis. Studies performed in gynogenic and xenograft models of lung cancer showed decreased tumor growth and metastasis in animals treated with PPARγ ligands. Furthermore, data are emerging from retrospective clinical studies that suggest a protective role for PPARγ ligands on the incidence of lung cancer. This review summarizes the research being conducted in this area and focuses on the mechanisms and potential therapeutic effects of PPARγ ligands as a novel anti-lung cancer treatment strategy.Keywords
This publication has 100 references indexed in Scilit:
- Rosiglitazone prevents the progression of preinvasive lung cancer in a murine modelCarcinogenesis, 2009
- Nicotine Stimulates PPARβ/δ Expression in Human Lung Carcinoma Cells through Activation of PI3K/mTOR and Suppression of AP-2αCancer Research, 2009
- Regression of Drug-Resistant Lung Cancer by the Combination of Rosiglitazone and CarboplatinClinical Cancer Research, 2008
- Activated PPARγ Targets Surface and Intracellular Signals That Inhibit the Proliferation of Lung Carcinoma CellsPPAR Research, 2008
- PPARs Mediate Lipid Signaling in Inflammation and CancerPPAR Research, 2008
- Ciglitazone mediates COX-2 dependent suppression of PGE2 in human non-small cell lung cancer cellsProstaglandins, Leukotrienes and Essential Fatty Acids, 2007
- Synergy between PPARγ Ligands and Platinum-Based Drugs in CancerCancer Cell, 2007
- Rosiglitazone, an Agonist of PPAR, Inhibits Non-Small Cell Carcinoma Cell Proliferation In Part through Activation of Tumor Sclerosis Complex-2PPAR Research, 2007
- Integrin-linked kinase: a cancer therapeutic target unique among its ILKNature Reviews Cancer, 2005
- PPARγ signaling exacerbates mammary gland tumor developmentGenes & Development, 2004